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Mesenchymal stem cells (MSCs) are ideal candidates for cell-based therapy aimed at tissue repair and 
immunomodulation. Aim. To study the survival of transplanted human MSCs from umbilical cord 
Wharton’s Jelly (hWJ-MSCs) in the animal model of experimental osteoarthritis (OA) in rats after inject-
ing cells into a knee joint and to explore the effect of collagen scaffold on the cell survival in vivo. 
Methods. MSC isolation and cultivation in vitro. Immunological phenotyping of propagated hWJ-MSCs 
was performed by fl ow cytometry. The retention of transplanted cells was studied by the PCR revealing 
of human specifi c sequences in genomic DNA extracted from animal tissues. Results. hWJ-MSCs, both 
individual and grown on scaffold, were used and it was shown by PCR that human alpha-satellite DNA 
was detected on the fi rst day in the immunocompetent OA animals inside the injured knee joint. In the 
collagen matrix (in the model of subcutaneous implantation) human alpha-satellite DNA was detected on 
the 5th day but was not detected on the 12th day. Conclusions. According to the PCR results, hWJ-MSCs 
survived in the OA animal model for a short period. Collagenic scaffold increased the residence time of 
donor cells in the recipients. hWJ-MSCs may be considered as a perspective cell source for the treatment 
of OA in human.
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Introduction
MSCs have been widely investigated over the years 
due to a combination of unique features such as their 
availability, ease of cultivation, multiplication ex vi-
vo, and positive therapeutic effects in animal models 
of various human diseases. A wide application of 
cell therapy with MSCs in practice depends on com-
plete understanding of mechanisms of their action. 
MSCs fi rst attracted attention due to their ability to 
differentiate into different directions [1, 2]. At pre-
sent, more and more researchers suggest that the re-
generative potential of MSCs is associated with pa-
racrine actions that coordinate the complex processes 
of restoration of damaged tissues and organs [3–7]. 
MSCs have been shown to secrete numerous growth 
factors like the transforming growth factor β, granu-
locyte-macrophage colony-stimulating factor, hepa-
tocyte growth factor, vascular endothelial growth fac-
tor, cytokines (interleukin 6, 10) and chemokines, 
prostaglandins, etc. [8–10].
In vitro MSC characteristics usually suggest their 
in vivo potency. However, the in vitro predictions do 
not always correlate with the in vivo results. Suc ces-
sful application of MSC-therapy to humans requires 
the characterization through in vivo animal models, 
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and xenogeneic transplantation is needed for the pi-
lot study of therapeutic features of human MSCs. 
Although MSCs are immunosuppressive and immu-
noprivileged and can be tolerated after allotransplan-
tation [11, 12], the cells cannot overcome the immu-
nological barrier in a xenogeneic environment [13]. 
However, the MSC therapeutic effi ciency was con-
fi rmed in several different cross-species models [14]. 
Numerous studies have demonstrated that the trans-
planted xenogeneic MSCs are able to avoid the im-
mune surveillance initially (e.g., during one week 
after transplantation), but are fi nally rejected even 
with immunosuppression [15]. Despite some limita-
tions of xenogeneic animal models in the study of 
human MSCs, the animal model assays improve our 
understanding of the mechanisms underlying the 
therapeutic effects.
MSCs have a signifi cant potential for the treat-
ment of OA, that is why several MSC-therapies are 
intensively developed for the OA-associated carti-
lage defects treatment [16, 17]. However, many ques-
tions remain unanswered such as the required cellu-
lar dose, the best source of MSCs, the fate of trans-
planted cells, etc.] [17]. hWJ-MSCs are considered 
to be much more proliferative, immunosuppressive, 
and even therapeutically active than other MSCs, and 
thus, more prospective for the OA treatment [18]. 
The MSCs survival after their transplantation is cru-
cial to the therapeutic effi cacy but there is little in-
formation about the fate of transplanted cells. In this 
context, the aim of the present short-term study was to 
examine the survival of hWJ-MSCs in immunocom-
petent OA rats in an early period following the trans-
plantation suggesting that at this stage the immune 
system contribution to the elimination of cells would 
not be essential. The survival of collagen scaffold im-
mobilized hWJ-MSCs was also assessed in vivo. 
Materials and Methods
Experimental Design
For the overall experimental design, one source of 
cells has been assayed in vivo in two site-directed 
implantation models for examining their retention. 
hWJ-MSCs were used after the second passage in 
culture. For Experiment 1 (local injection), culture ex-
panded hWJ-MSCs were injected into a knee joint. For 
Experiment 2, the cells were seeded in 3-D scaffolds 
and implanted subcutaneously. All the experiments 
were performed without immunosuppression. To track 
the fate of the donor hMSCs, the tissue samples were 
collected at different time points for PCR analysis.
Laboratory animals
Wistar rats (males with we ight 180–200 g) and mo-
use line BALB/c were used as experimental animals. 
The animals were kept under standard conditions. 
All manipulations with animals were carried out in 
accordance with the requirements of Guide for the 
Care and Use of laboratory Animals [19] and the law 
of Ukraine N 3447-IV of 21.02.2006 «The protec-
tion of animals from cruel behavior» [20].
Isolation and culture of hWJ-MSCs
The human umbilical cord samples were collected 
after informed consent of puerpera and processed by 
the method described earlier [21]. To confi rm a prop-
er surface mar kers’ expression (CD73, CD90, CD105 
and CD34), the ex vivo propagated cells were ana-
lysed by fl ow cytometry at passage 2 [22]. FACS-
analysis of the MSC markers expression (MAbs 
CD105, CD90, CD73 – BD, USA) was performed with 
BD FACSAria cell sorter (Becton Dickinson Bio-
sciences, San Jose, CA, USA) and BD FACSDiva 
software (v 6.1.2). 
Obtaining the experimental model
of osteoarthritis with I-acetic acid in rats
The animal models were established by means of 
intra-articular injection of iodine-acetic acid. Rats 
were injected with 0.1 ml of iodine-acetic acid (3 mg 
of iodine-acetic acid in 50 μl of 0.9 % NaCl) and 
monitored for signs of arthritis onset based on paw 
swelling and clinical scores [23]. Animals with oste-
oarthritic signs (score 2, pronounced edema) were 
enrolled in the study (n = 19). On day 7, osteoar-
thritic and intact (n = 10) animals were injected with 
1.5  106 cells in 100 μl of PBS. Additionally, two 
animals (sham-operated males) received injections 
of an equivalent volume of PBS.
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Fabrication of collagen scaffolds
and cell seeding.
Type I collagen was extracted from bovine tendons us-
ing the pepsin-based acidic extraction method described 
in [24], lyophilized, and stored at – 20 °C for further 
application. Porous collagen scaffolds were prepared 
by freeze-drying the collagen type I solution (10 mg/
ml) in 0.1 M acetic acid as described earlier [25]. The 
scaffolds were UV-treated, swollen overnight in 0.1 M 
HEPES pH 7.4, and then equilibrated in cell cultiva-
tion medium for 24 hours at 37 °C and 5 % CO2. 
Approximately 1 × 106–1.5 × 106 hWJ-MSCs were 
seeded per 1 cm2 of scaffold. The cells were culti-
vated on scaffold for 24 hours at 37 °C and 5 % CO2 
prior to implantation. After implantation for differ-
ent time points, the scaffolds were removed.
Isolation of DNA
Genomic DNA was extracted from synovial fl uid using 
the salt out method (according to Grinberg,1989) [26]. 
DNA from synovial tissues (swabs) and scaffolds was 
isolated as previously described by the method of 
Bruijn et al. [27]. The DNA concentration and purity 
were determined by optical density using the Thermo 
Scientifi c NanoDrop 2000 UV-Vis spectrophotometer.
Polymerase chain reaction
To detect transplanted human cells in rats and mice, 
the polymerase chain reaction analysis was perfor-
med using primers to amplify human-specifi c 850-
bp fragment of the alpha-satellite DNA on human 
chromosome 17 [28]; polymerase chain reaction was 
performed as described in the work of Becker et al. 
[28]. Each reaction contained the same amount of 
genomic DNA template (100 ng in 20 μl of reaction 
mixture). DNA from cultured hWJ-MSCs served as 
a positive control and DNA from an untreated ani-
mal was used as a negative control.
Oligonucleotides used for PCR as described by 
Warburton et al. [29]:
Cr17_1a f (5’-GGG ATA ATT TCA GCT GAC 
TAA ACA G-3 ‘) 15..39
Cr17_2b r (5’TTC CGT TTA GTT AGG TGC 
AGT TAT C-3 ‘) 867..891 
Separation of amplifi cation products was perfor-
med in 1.2 % agarose gel in TAE with subsequent 
visualization under ultraviolet light after ethidium 
bromide staining. GeneRuler 100 bp DNA Ladder 
(«Fermentas», Lithuania) was used as a marker of 
PCR product fragment length.
Results and Discussion
hWJ-MSCs were isolated from Wharton’s Jelly, 
propagated in culture, harvested at the second pas-
sage and confi rmed to be MSCs according to the 
International Society for Cellular Therapy’s minimal 
criteria for defi ning MSCs. In accordance with the 
FACS analysis hWJ-MSCs were positive for CD73, 
CD90, and CD105 antigens more than 90 % and 
were negative for CD34 antigen (< 2 %). The cell 
viability was confi rmed with trypan blue dye exclu-
sion (> 95 %). The retention of hWJ-MSCs in the 
animal models was detected through the presence of 
the human-specifi c alpha-satellite DNA in the ana-
lysed samples. A sensitive PCR assay was performed 
for detection of the human cells in animal tissues. 
The method has a high sensitivity due to the highly 
repetitive alpha-satellite sequence. PCR primers we-
Fig. 1. Electrophoregram of amplifi cation product with primers 
to the human alpha-satellite DNA in 1.2% agarose gel. 1 – hWJ-
MSCs DNA; 2 – marker 100 bp DNA Ladder (Fermentas)
1000 bp
500 bp
850 bp
1 2
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re specifi c for the hMSC donor DNA with the sensi-
tivity of 1/105–1/106, in serial dilutions. The electro-
phoregram of alpha-human DNA PCR product is 
shown in Fig. 1.
To study the survival of hWJ-MSCs in OA animal, 
the experimental rats were injected with cells through 
intra-articular route. The animals were sacrifi ced ac-
cording to the standard protocols for euthanasia after 
0.5, 2, 24 hours and 7 days of transplantation. The 
number of animals selected for PCR analysis was 
minimized to two at each harvest time point (Table 1). 
The joints were opened, the synovial washouts and 
tissues of hWJ-MSCs injected (injured and healthy) 
and control joints were used to isolate DNA, which 
was used as a template for PCR (Fig. 2). 
As seen from the results of PCR, the human DNA 
was detected in joint cavity, at least during the fi rst 
day. At the 7th day of transplantation, the alpha-satel-
lite DNA in amplifi cation reaction was not detected. 
Early cell loss was observed in both OA-induced and 
intact animal groups. The exact date of human DNA 
clearance remains unclear because the samples were 
harvested on days 1 and 7 after in vivo hWJ-MSCs 
delivery. 
It is known that biocompatible 3-D scaffolds can 
prolong the the transplanted cells survival in the in-
jury site. In order to examine whether the collagen 
scaffolds improve the hWJ-MSCs survival in the xe-
nogeneic setting, the same hWJ-MSCs were seeded 
to scaffolds and subcutaneously implanted into im-
munocompetent mice without appropriate immune 
suppression. The collagen matrices were recovered 
from the implantation sites with different time points 
at 1, 5 and 12 days for the isolation of genomic DNA. 
The results of PCR for the presence of human DNA 
in the grafts in mice are shown in Fig. 3. 
The PCR assay demonstrated the complete loss of 
human DNA in the samples at the 12th day. This sug-
gests that hWJ-MSCs survived in the BALB/c mice at 
least for the fi rst week of post-transplantation. 
Using a species-specifi c PCR analysis of the hu-
man genomic DNA we have revealed short-time sur-
vival of the transplanted cells in two different animal 
models in vivo. It is known that a local administra-
tion of cells promotes a direct physical contact of 
Table 1. hWJ-MSC detection by alpha-satellite DNA PCR
Post
transplantation
time
PCR-positive rats
with osteoarthritis
PCR-positive
intact rats
Sinovial
washout Sinovium
Sinovial
washout Sinovium
30 min (n = 2) 2 2 2 2
2h        (n = 2) 2 2 2 2
24 h     (n = 2) 2 2 2 2
7 days  (n = 2) 0 0 0 0
Fig. 2. The results of PCR for the presence of human alpha-
satellite DNA samples from affected joints cavities of rats after 
administration of hWJ-MSCs at different time points. 1 – fl ush 
joint after administration of PBS (control) 30 min; 2 – synovial 
washout, 30 min; 3 – synovial tissue, 30 min; 4 – molecular we-
ight marker, 100 bp DNA Ladder (Fermentas); 5 – hWJ-MSCs; 
6 – synovial washout, 24h ; 7 – synovial washout, 7 days; 8 – 
synovial washout after administration of PBS (control), 7 days
       1          2          3          4          5          6           7         8
       1               2              3               4               5                6
Fig. 3. Results of PCR for the presence of human alpha-satellite 
DNA samples from 3-D collagen matrices populated with hWJ-
MSCs after subcutaneous implantation into the BALB/c mice. 1 – 
3-D hWJ-MSCs -seeded matrix prior to implantation; 2 – 24 
hours after implantation; 3 – 5 days after implantation; 4 – hWJ-
MSCs (positive control); 5 – molecular weight marker, 100 bp 
DNA Ladder (Fermentas); 6 – 12 days after implantation
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donor and recipient cells which leads to a more ef-
fi cient exchange of the molecular signals that coor-
dinate regenerative processes. We have observed a 
sudden cell loss during the fi rst days following the 
local hWJ-MSCs transplantation in the applied ex-
perimental model of OA. The early cell loss during 
intra-articular injection can occur for a variety of 
reasons. For example, the infl ux of monocytes/
macrophages into the injured knee joint provides 
unfavourable conditions for the exogenous stem 
cell survival, confi rmed by the absence of human 
DNA in the samples. On the other hand, hypoxia 
and serum deprivation within the fi rst 24 hours af-
ter transplantation contribute to the cell death. 
Additionally, a sharp decrease in detectability of 
the human DNA in animal tissues may be associat-
ed with the PCR limitation. All mentioned above 
reasons can be relevant. In contrast, the hWJ-MSCs 
immobilised in a scaffold avoided an immediate 
contact with the host immune cells in the early 
post-transplantation period as they were partially 
protected and thus did not undergo a direct immune 
attack by the host within the fi rst week after trans-
plantation. Moreover, a scaffold partially mimics in 
vivo conditions that prolongs the cell survival. 
There was an appreciable difference in the survival 
time of the hWJ-MSCs immobilized on a scaffold 
and transplanted as a three-dimensional structure 
compared to those transplanted as the cell suspen-
sion. A tendency to early death of the transplanted 
human MSCs in immunocompetent animals is 
shown in recent studies [30, 31]. Toupet et al. re-
ported that survival and biodistribution of xenoge-
neic MSCs are not affected by the degree of infl am-
mation in arthritis [31]. On the other hand several 
studies indicated that even such short-term viability 
of transplanted cells (one day) can be suffi cient to 
initiate the regeneration of damaged tissues [15, 32, 
33]. Therefore the therapeutic potential and func-
tional activity of human MSCs may initially be 
tested in such animal models. Our data suggest that 
the optimization of experimental protocols for the 
hWJ-MSCs isolation, cell preconditioning and cell 
formulation are required to improve the cell sur-
vival after transplantation.
Conclusions
hWJ-MSCs were applied in the OA animal model to 
assess a potential of these cells for treatment of OA. 
According to the PCR results, hWJ-MSCs survived 
in the OA animals for a short period. The collagen 
scaffold increased the cell residence time in recipi-
ents. hWJ-MSCs may be considered as a perspective 
cell source for the treatment of OA in humans.
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Моніторинг трансплантованих мезенхімальних
 стовбурових клітин Вартонового
студня пуповини людини in vivo у ксеногених системах
М. В. Ковальчук, Н. С. Шувалова,
Я. О. Похоленко, М. В. Драгулян, Т. П. Гулько,
О. Г. Дерябіна, В. А. Кордюм
Мезенхімальні стовбурові клітини (МСК) є ідеальними кан-
дидатами для відновлення тканин та імуномодуляції при 
клітинній терапії. Мета. Вивчити виживання транспланто-
ваних МСК Вартанового студню пуповини людини (МСК-
ВС) на моделі експериментального остеоартрозу у щурів 
(введення клітин в колінний суглоб) та дослідити вплив кол-
лагенового матриксу на виживання МСК-ВС in vivo. Ме-
тоди. Виділення і культивування МСК-ВС in vitro. Імуно ло-
гічне фенотипування мультиплікованих МСК-ВС проведено 
за допомогою проточної цитофлуорометрії. Збере жен ня 
трансплантованих клітин вивчали за допомогою ПЛР, що 
виявляє специфічні для людини послідовності в геномній 
ДНК, ізольованій з тканин тварин. Результи Використано 
індивідуальні та вирощені на матриксі МСК-ВС, ПЛР по-
казано, що альфа-сателітна ДНК людини в пошкодженому 
суглобі у імунокомпетентних травмованих тварин виявля-
лась за добу. У колагеновому матриксі (в моделі підшкірної 
імплантації) ДНК людини була виявлена на 5, але не детек-
тувалась на 12 добу. Висновки. За результатами ПЛР МСК-
ВС виживали у тварин з остеоартрітом протягом нетривало-
го часу. Кола ге но вий матрикс збільшував тривалість пере-
бування МСК-ВС у реципієнтів. МСК-ВС можуть розгляда-
тися як перспектив не джерело клітин для лікування остео-
артриту у людини. 
Ключов і  слова: МСК-ВС, альфа-сателітна ДНК, 3-D мат-
рикс, виживання клітин, ПЛР.
Мониторинг трансплантированных мезенхимальных 
стволовых клеток Вартонового студня пуповины челове-
ка in vivo в ксеногенных системах
М. В. Ковальчук, Н. С. Шувалова, Я. А. Похоленко,
М. В. Драгулян, Т. П. Гулько, Е. Г. Дерябина, В. А. Кордюм
Мезенхимальные стволовые клетки (МСК) являются идеальны-
ми кандидатами для восстановление тканей и иммуномодуля-
ции при клеточной терапии. Цель. Изучить выживание транс-
плантированных МСК Варто но во го студня пуповины человека 
(МСК-ВС) на модели экспериментального остеоартроза у крыс 
(введение клеток в коленный сустав), и исследовать влияние 
коллагенового матрикса на выживание МСК-ВС in vivo. Методы. 
Вы де ление и культивирование МСК-ВС in vitro. Имму но ло ги-
ческое фенотипирование мультиплицированных МСК-ВС про-
ведено с помощью проточной цитофлуорометрии. Сохра не ние 
трансплантированных клеток изучали с помощью ПЦР, выявля-
ющей специфические для человека последовательности в ге-
номной ДНК, изолированной из тканей животных. Результы. 
Исследование индивидуальних и выращенные на матриксе 
МСК-ВС, с помощью ПЦР, показало, что альфа-сателлитная 
ДНК человека детектировалась в первые сутки у иммунокомпе-
тентных животных в поврежденном суставе. В коллагеновом 
матриксе (в модели подкожной имплантации) ДНК человека 
была обнаружена на 5, но не детектировалась на 12 сутки. Вы-
воды. По результатам ПЦР МСК-ВС выживали у жи вотных с 
остеоартритом в течение короткого периода. Коллагеновый мат-
рикс увеличивал продолжительность пре бывания МСК-ВС у 
реципиентов. МСК-ВС могут рассматриваться как перспектив-
ный источник клеток для лечения остеоартрита у человека.
Ключевые  слова: МСК-ВС, альфа-сателлитная ДНК, 3-D 
мат рикс, вы живание клеток, ПЦР.
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